Dr David Irvine
- Affiliate (School of Cancer Sciences)
email:
David.Irvine@glasgow.ac.uk
R321 Level 3, Paul O'Gorman Leukaemia Res Cent, Gartnavel General Hospital, Glasgow G12 0YN
Publications
2021
Horne, G. A. , Laird, J., Latif, A.-L., Irvine, D., Wilson, M. and Douglas, K. (2021) The implications of CAR-T cell therapy on apheresis services: a Scottish perspective. Journal of Clinical Apheresis, 36(3), pp. 513-515. (doi: 10.1002/jca.21871) (PMID:33378123)
2020
Kinstrie, R. et al. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34(6), pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5) (PMID:31896780) (PMCID:PMC7272220)
2016
Irvine, D. A. et al. (2016) Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Scientific Reports, 6, 25476. (doi: 10.1038/srep25476) (PMID:27157927) (PMCID:PMC4860619)
2014
Toofan, P., Irvine, D., Hopcroft, L. , Copland, M. and Wheadon, H. (2014) The role of the bone morphogenetic proteins in leukaemic stem cell persistence. Biochemical Society Transactions, 42(4), pp. 809-815. (doi: 10.1042/BST20140037)
2013
Cramer-Morales, K. et al. (2013) Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood, 122(7), pp. 1293-1304. (doi: 10.1182/blood-2013-05-501072)
2012
Flis, K., Irvine, D., Copland, M. , Bhatia, R. and Skorski, T. (2012) Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. Leukemia and Lymphoma, 53(12), pp. 2474-2478. (doi: 10.3109/10428194.2012.696313)
Irvine, D.A. and Copland, M. (2012) Targeting hedgehog in hematologic malignancy. Blood, 119(10), pp. 2196-2204. (doi: 10.1182/blood-2011-10-383752)
2011
Gallipoli, P., Shepherd, P., Irvine, D., Drummond, M. and Holyoake, T. (2011) Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. British Journal of Haematology, 155(1), pp. 128-130. (doi: 10.1111/j.1365-2141.2011.08653.x)
2010
Irvine, D. A., Heaney, N. B. and Holyoake, T. L. (2010) Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors - A synthesis of clinical and laboratory data. Blood Reviews, 24(1), pp. 1-9. (doi: 10.1016/j.blre.2009.11.002)
Articles
Horne, G. A. , Laird, J., Latif, A.-L., Irvine, D., Wilson, M. and Douglas, K. (2021) The implications of CAR-T cell therapy on apheresis services: a Scottish perspective. Journal of Clinical Apheresis, 36(3), pp. 513-515. (doi: 10.1002/jca.21871) (PMID:33378123)
Kinstrie, R. et al. (2020) CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Leukemia, 34(6), pp. 1613-1625. (doi: 10.1038/s41375-019-0684-5) (PMID:31896780) (PMCID:PMC7272220)
Irvine, D. A. et al. (2016) Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. Scientific Reports, 6, 25476. (doi: 10.1038/srep25476) (PMID:27157927) (PMCID:PMC4860619)
Toofan, P., Irvine, D., Hopcroft, L. , Copland, M. and Wheadon, H. (2014) The role of the bone morphogenetic proteins in leukaemic stem cell persistence. Biochemical Society Transactions, 42(4), pp. 809-815. (doi: 10.1042/BST20140037)
Cramer-Morales, K. et al. (2013) Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood, 122(7), pp. 1293-1304. (doi: 10.1182/blood-2013-05-501072)
Flis, K., Irvine, D., Copland, M. , Bhatia, R. and Skorski, T. (2012) Chronic myeloid leukemia stem cells display alterations in expression of genes involved in oxidative phosphorylation. Leukemia and Lymphoma, 53(12), pp. 2474-2478. (doi: 10.3109/10428194.2012.696313)
Irvine, D.A. and Copland, M. (2012) Targeting hedgehog in hematologic malignancy. Blood, 119(10), pp. 2196-2204. (doi: 10.1182/blood-2011-10-383752)
Gallipoli, P., Shepherd, P., Irvine, D., Drummond, M. and Holyoake, T. (2011) Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. British Journal of Haematology, 155(1), pp. 128-130. (doi: 10.1111/j.1365-2141.2011.08653.x)
Irvine, D. A., Heaney, N. B. and Holyoake, T. L. (2010) Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors - A synthesis of clinical and laboratory data. Blood Reviews, 24(1), pp. 1-9. (doi: 10.1016/j.blre.2009.11.002)